Ana Carolina Dantas
Research Subjects
Research Interests
Ana Carolina Dantas has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ariel Bardach
Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina
1 shared publication - Carlos Fernando Mendoza
Pfizer Inc., Mexico City, Mexico.
1 shared publication - Carolina M. Carballo
Vaccines, Medical, Pfizer Inc., Buenos Aires City C1437, Argentina
1 shared publication - Carolina Moreno
Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina
1 shared publication - Cecilia Inés Loudet
Hospital General San Martin de La Plata, Buenos Aires, Argentina
1 shared publication - Emiliano Navarro
Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires City C1414, Argentina
1 shared publication
Latest Publications
- Open Access
- 24 April 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (5) , 669
COVID-19 Disease and Economic Burden to Healthcare Systems in Adults in Six Latin American Countries Before Nationwide Vaccination Program: Ministry of Health Database Assessment and Literature Review
The COVID-19 pandemic imposed a substantial burden on healthcare systems worldwide, yet reliable data on COVID-19 morbidity, mortality, and healthcare costs in Latin America remain limited. This study explored the disease and economic burden of COVID-19 in Argentina, Brazil, Chile, Colombia, Mexico, and Peru during the pre-vaccination period. Using national databases and a systematic review of the literature, we analyzed data on adults aged 18 and older, reporting cases, death rates, years of life lost, excess mortality, and direct medical costs. Before vaccination programs began, the average COVID-19 incidence rate was 6741 per 100,000 adults. Of these, 91% were mild cases, 7% moderate/severe, and 2% critical. Among 2,201,816 hospitalizations, 27.8% required intensive care, and 17.5% required mechanical ventilation. Excess mortality ranged from 76 to 557 per 100,000, and years of life lost spanned 241,089 to 3,312,346. Direct medical costs ranged from USD 258 million to USD 10,437 million, representing 2–5% of national health expenditures. The findings highlight significant variability across countries and provide crucial insights to help policymakers to make informed decisions and allocate resources effectively to improve national strategies around surveillance, preventive and treatment strategies to control the spread of COVID-19 disease in the future.
- 24 April 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (5) , 669
Open AccessCOVID-19 Disease and Economic Burden to Healthcare Systems in Adults in Six Latin American Countries Before Nationwide Vaccination Program: Ministry of Health Database Assessment and Literature Review
The COVID-19 pandemic imposed a substantial burden on healthcare systems worldwide, yet reliable data on COVID-19 morbidity, mortality, and healthcare costs in Latin America remain limited. This study explored the disease and economic burden of COVID-19 in Argentina, Brazil, Chile, Colombia, Mexico, and Peru during the pre-vaccination period. Using national databases and a systematic review of the literature, we analyzed data on adults aged 18 and older, reporting cases, death rates, years of life lost, excess mortality, and direct medical costs. Before vaccination programs began, the average COVID-19 incidence rate was 6741 per 100,000 adults. Of these, 91% were mild cases, 7% moderate/severe, and 2% critical. Among 2,201,816 hospitalizations, 27.8% required intensive care, and 17.5% required mechanical ventilation. Excess mortality ranged from 76 to 557 per 100,000, and years of life lost spanned 241,089 to 3,312,346. Direct medical costs ranged from USD 258 million to USD 10,437 million, representing 2–5% of national health expenditures. The findings highlight significant variability across countries and provide crucial insights to help policymakers to make informed decisions and allocate resources effectively to improve national strategies around surveillance, preventive and treatment strategies to control the spread of COVID-19 disease in the future.